---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-24-000010"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T01:15:31.907027+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aurinia reports 2023 net product revenue up 53% to $158.5M; ends strategic review, initiates $150M buyback

## Summary
- Net product revenue $158.5M (+53% YoY); net loss $78.0M ($0.54/shr) vs $108.2M loss in 2022.
- Discontinues AUR200/AUR300 development; expects $11-15M Q1'24 charge and $50-55M annual savings; headcount cut ≥25% (non-commercial).
- Board authorizes up to $150M share repurchase; max subject to Canadian regulatory approval; purchases start Feb 21, 2024.
- Strategic review concluded after engaging 60+ parties; one non-binding expression of interest did not lead to formal offer.
- Reaffirms 2024 net product revenue guidance of $200-220M; 2,066 patients on LUPKYNIS at year-end (vs 1,525).

## SEC filing metadata
- accession: 0001600620-24-000010
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000010/0001600620-24-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000010/auph-20240215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-24-000010
- JSON: https://secwatch.observer/filing/0001600620-24-000010.json
- Plain text: https://secwatch.observer/filing/0001600620-24-000010.txt

## Key facts
- Earnings Releases
  Aurinia Pharmaceuticals Inc. updated its quarter and year ended December 31, 2023 guidance (reaffirmed).
  - Period: quarter and year ended December 31, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On February 15, 2024, Aurinia Pharmaceuticals Inc. (Aurinia) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000010/0001600620-24-000010-index.htm
- Restructurings & Charges
  Aurinia Pharmaceuticals Inc. announced a restructuring with charges of approximately $11 - $15 million affecting AUR200 and AUR300 research and development programs.
  - Type: restructuring
  - Charge: approximately $11 - $15 million
  - Affected area: AUR200 and AUR300 research and development programs
  source text: This will result in a one-time charge in the first quarter of 2024 of approximately $11 - $15 million and expected operational cost savings of approximately $50 - $55 million annually, with approximately 75% being recognized in 2024 excluding the one-time restructuring charge in the first quarter of 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000010/0001600620-24-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.